Juniper Biomedical
Private Company
Total funding raised: $2.5M
Overview
Juniper Biomedical is pioneering a next-generation neuromodulation platform targeting the large and underserved pelvic health market. The company's core innovation is a micro-implant that couples directly to distal peripheral nerves, enabling precise, low-power stimulation for conditions such as urinary and bowel incontinence. With a seasoned leadership team and a platform approach applicable to multiple indications, Juniper is positioning itself to offer a safer, less invasive alternative to current high-powered, imprecise systems. The company is in the development stage, building its technology and team ahead of anticipated clinical trials.
Technology Platform
A precision neuromodulation platform featuring a micro-implant that couples directly to distal peripheral nerves for selective, low-power stimulation, as opposed to traditional high-power volume conduction systems.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Juniper competes in the neuromodulation space against large, established players like Medtronic (InterStim) and Axonics, whose systems are based on sacral nerve stimulation via volume conduction. Its primary competitive advantage is the promise of greater precision, lower power, and a less invasive implant. It also indirectly competes with pharmaceuticals, pelvic floor physical therapy, and surgical slings.